4 September 2008 - Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.The Phase 3 trial is being conducted in 41 hospitals across North America, Argentina and Germany, and is the final clinical step before Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the United States... [PDF] Pharmaxis' Press Release -
